SELLAS Life Sciences Group Inc buy El_Zocko
Start price
27.02.15
/
50%
€45,810
Target price
06.03.15
€55,500
Performance (%)
26.39%
End price
06.03.15
€57,900
Summary
This prediction ended on 06.03.15 with a price of €57,900. The prediction had a final performance of 26.39%. El_Zocko has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 1.520% | 1.520% | -13.150% | -84.746% |
| iShares Core DAX® | 1.937% | 1.473% | 18.596% | 15.757% |
| iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% | 35.363% |
| iShares Nikkei 225® | 1.938% | 4.205% | 17.502% | 10.532% |
| iShares S&P 500 | -0.023% | 0.109% | 24.843% | 36.692% |
Comments by El_Zocko for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
GALENA BIOPHARMA
Trendwende geschafft? Ich sage: ja!